Rochester, Minn.-based Mayo Clinic researcher Raseen Tariq, MBBS, led a meta-analysis of 16 studies comprising 7,703 patients examining gastric acid suppressants’ use and how it affected C. diff infections.
Here’s what she found.
1. Of the total patient base, 1,525 patients developed recurrent CDI.
2. Approximately 22.1 percent gastric acid suppression patients developed recurrent CDI compared to 17.3 percent who developed CDI without gastric acid suppression.
3. A subgroup analyses of studies adjusting for age and confounders confirmed an increased infection risk with gastric acid suppressant use.
Researchers concluded, “Meta-analyses of observational studies suggest that patients who receive gastric acid suppressants may be at increased risk for recurrent CDI.” However, the researchers cautioned that the data should be cautiously interpreted because the studies “may be confounded owing to the observational design of the individual studies.”
More articles on gastroenterology:
GI leader to know: Dr. Brett Thorpe of Provo Gastroenterology
Two-time colorectal cancer survivor Dr. Samuel Pace spends retirement promoting cancer awareness: 4 key notes
The Giant Colon tours Canada to raise colon cancer awareness: 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.